Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes

doi:10.1084/jem.179.3.1005

This Article

	Full Text (PDF, 438K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Bakker, A. B.
	Articles by Figdor, C. G.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Bakker, A. B.
	Articles by Figdor, C. G.


Social Bookmarking

	What's this?

ARTICLES

Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes

AB Bakker, MW Schreurs, AJ de Boer, Y Kawakami, SA Rosenberg, GJ Adema and CG Figdor
Division of Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Amsterdam.

We recently isolated a cDNA clone that encodes the melanocyte lineage- specific antigen glycoprotein (gp)100. Antibodies directed against gp100 are an important tool in the diagnosis of human melanoma. Since the gp100 antigen is highly expressed in melanocytic cells, we investigated whether this antigen might serve as a target for antimelanoma cytotoxic T lymphocytes (CTL). Here, we demonstrate that cytotoxic tumor-infiltrating lymphocytes (TIL) derived from a melanoma patient (TIL 1200) are directed against gp100. HLA-A2.1+ melanoma cells are lysed by TIL from this patient. In addition, murine double transfectants, expressing both HLA-A2.1 and gp100, are lysed by TIL 1200, whereas transfectants expressing only HLA-A2.1 are not susceptible to lysis. Furthermore, the HLA-A2.1+ melanoma cell line BLM, which lacks gp100 expression and is resistant to lysis, becomes susceptible after transfection of gp100 cDNA. Finally, HLA-A2.1+ normal melanocytes are lysed by TIL 1200. These data demonstrate that the melanocyte differentiation antigen gp100 can be recognized in the context of HLA-A2.1 by CTL from a melanoma patient. Gp100 may therefore constitute a useful target for specific immunotherapy against melanoma, provided that no unacceptable cytotoxicity towards normal tissue is observed.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Tacken, P. J., Joosten, B., Reddy, A., Wu, D., Eek, A., Laverman, P., Kretz-Rommel, A., Adema, G. J., Torensma, R., Figdor, C. G. (2008). No Advantage of Cell-Penetrating Peptides over Receptor-Specific Antibodies in Targeting Antigen to Human Dendritic Cells for Cross-Presentation. J. Immunol. 180: 7687-7696 [Abstract] [Full Text]
Puri, N., Ahmed, S., Janamanchi, V., Tretiakova, M., Zumba, O., Krausz, T., Jagadeeswaran, R., Salgia, R. (2007). c-Met Is a Potentially New Therapeutic Target for Treatment of Human Melanoma. Clin. Cancer Res. 13: 2246-2253 [Abstract] [Full Text]
Kono, M., Dunn, I. S., Durda, P. J., Butera, D., Rose, L. B., Haggerty, T. J., Benson, E. M., Kurnick, J. T. (2006). Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression. Mol Cancer Res 4: 779-792 [Abstract] [Full Text]
Perales, M.-A., Diab, A., Cohen, A. D., Huggins, D. W., Guevara-Patino, J. A., Hubbard, V. M., Engelhorn, M. E., Kochman, A. A., Eng, J. M., Mortazavi, F., Alpdogan, O., Terwey, T. H., Heller, G., Wolchok, J. D., Houghton, A. N., van den Brink, M. R. M. (2006). DNA Immunization against Tissue-Restricted Antigens Enhances Tumor Immunity after Allogeneic Hemopoietic Stem Cell Transplantation. J. Immunol. 177: 4159-4167 [Abstract] [Full Text]
Cohen, A. D., Diab, A., Perales, M.-A., Wolchok, J. D., Rizzuto, G., Merghoub, T., Huggins, D., Liu, C., Turk, M. J., Restifo, N. P., Sakaguchi, S., Houghton, A. N. (2006). Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity.. Cancer Res. 66: 4904-4912 [Abstract] [Full Text]
van Baren, N., Bonnet, M.-C., Dreno, B., Khammari, A., Dorval, T., Piperno-Neumann, S., Lienard, D., Speiser, D., Marchand, M., Brichard, V. G., Escudier, B., Negrier, S., Dietrich, P.-Y., Maraninchi, D., Osanto, S., Meyer, R. G., Ritter, G., Moingeon, P., Tartaglia, J., van der Bruggen, P., Coulie, P. G., Boon, T. (2005). Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells. JCO 23: 9008-9021 [Abstract] [Full Text]
Goldberg, S. M., Bartido, S. M., Gardner, J. P., Guevara-Patino, J. A., Montgomery, S. C., Perales, M.-A., Maughan, M. F., Dempsey, J., Donovan, G. P., Olson, W. C., Houghton, A. N., Wolchok, J. D. (2005). Comparison of Two Cancer Vaccines Targeting Tyrosinase: Plasmid DNA and Recombinant Alphavirus Replicon Particles. Clin. Cancer Res. 11: 8114-8121 [Abstract] [Full Text]
de Vries, I. J. M., Bernsen, M. R., Lesterhuis, W. J., Scharenborg, N. M., Strijk, S. P., Gerritsen, M.-J. P., Ruiter, D. J., Figdor, C. G., Punt, C. J.A., Adema, G. J. (2005). Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical Outcome. JCO 23: 5779-5787 [Abstract] [Full Text]
Andersen, M. H., Reker, S., thor Stratem, P., Gehl, J., Geertsen, P., Becker, J. C. (2005). Concomitant Administration of Interleukin-2 During Therapeutic Vaccinations Against Cancer: The Good, the Bad, or the Evil?. JCO 23: 5265-5267 [Full Text]
Hoashi, T., Watabe, H., Muller, J., Yamaguchi, Y., Vieira, W. D., Hearing, V. J. (2005). MART-1 Is Required for the Function of the Melanosomal Matrix Protein PMEL17/GP100 and the Maturation of Melanosomes. J. Biol. Chem. 280: 14006-14016 [Abstract] [Full Text]
Germeau, C., Ma, W., Schiavetti, F., Lurquin, C., Henry, E., Vigneron, N., Brasseur, F., Lethe, B., De Plaen, E., Velu, T., Boon, T., Coulie, P. G. (2005). High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. JEM 201: 241-248 [Abstract] [Full Text]
Nakatsura, T., Komori, H., Kubo, T., Yoshitake, Y., Senju, S., Katagiri, T., Furukawa, Y., Ogawa, M., Nakamura, Y., Nishimura, Y. (2004). Mouse Homologue of a Novel Human Oncofetal Antigen, Glypican-3, Evokes T-Cell-Mediated Tumor Rejection without Autoimmune Reactions in Mice. Clin. Cancer Res. 10: 8630-8640 [Abstract] [Full Text]
Narayanan, K., Jaramillo, A., Benshoff, N. D., Campbell, L. G., Fleming, T. P., Dietz, J. R., Mohanakumar, T. (2004). Response of Established Human Breast Tumors to Vaccination with Mammaglobin-A cDNA. JNCI J Natl Cancer Inst 96: 1388-1396 [Abstract] [Full Text]
PURI, N., ELLER, M. S., BYERS, H. R., DYKSTRA, S., KUBERA, J., GILCHREST, B. A. (2004). Telomere-based DNA damage responses: a new approach to melanoma. FASEB J. 18: 1373-1381 [Abstract] [Full Text]
Yasumoto, K.-i., Watabe, H., Valencia, J. C., Kushimoto, T., Kobayashi, T., Appella, E., Hearing, V. J. (2004). Epitope Mapping of the Melanosomal Matrix Protein gp100 (PMEL17): RAPID PROCESSING IN THE ENDOPLASMIC RETICULUM AND GLYCOSYLATION IN THE EARLY GOLGI COMPARTMENT. J. Biol. Chem. 279: 28330-28338 [Abstract] [Full Text]
Ramirez, F., Ghani, Y., Stauss, H. (2004). Incomplete tolerance to the tumour-associated antigen MDM2. Int Immunol 16: 327-334 [Abstract] [Full Text]
de Vries, I. J. M., Lesterhuis, W. J., Scharenborg, N. M., Engelen, L. P. H., Ruiter, D. J., Gerritsen, M.-J. P., Croockewit, S., Britten, C. M., Torensma, R., Adema, G. J., Figdor, C. G., Punt, C. J. A. (2003). Maturation of Dendritic Cells Is a Prerequisite for Inducing Immune Responses in Advanced Melanoma Patients. Clin. Cancer Res. 9: 5091-5100 [Abstract] [Full Text]
de Rijke, B., Fredrix, H., Zoetbrood, A., Scherpen, F., Witteveen, H., de Witte, T., van de Wiel-van Kemenade, E., Dolstra, H. (2003). Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: relevance for precursor B-ALL-specific immunotherapy. Blood 102: 2885-2891 [Abstract] [Full Text]
Schreurs, M. W. J., Scholten, K. B. J., Kueter, E. W. M., Ruizendaal, J. J., Meijer, C. J. L. M., Hooijberg, E. (2003). In Vitro Generation and Life Span Extension of Human Papillomavirus Type 16-Specific, Healthy Donor-Derived CTL Clones. J. Immunol. 171: 2912-2921 [Abstract] [Full Text]
Denkberg, G., Lev, A., Eisenbach, L., Benhar, I., Reiter, Y. (2003). Selective Targeting of Melanoma and APCs Using a Recombinant Antibody with TCR-Like Specificity Directed Toward a Melanoma Differentiation Antigen. J. Immunol. 171: 2197-2207 [Abstract] [Full Text]
Tanioka, T., Hattori, A., Masuda, S., Nomura, Y., Nakayama, H., Mizutani, S., Tsujimoto, M. (2003). Human Leukocyte-derived Arginine Aminopeptidase: THE THIRD MEMBER OF THE OXYTOCINASE SUBFAMILY OF AMINOPEPTIDASES. J. Biol. Chem. 278: 32275-32283 [Abstract] [Full Text]
Gold, J. S., Ferrone, C. R., Guevara-Patino, J. A., Hawkins, W. G., Dyall, R., Engelhorn, M. E., Wolchok, J. D., Lewis, J. J., Houghton, A. N. (2003). A Single Heteroclitic Epitope Determines Cancer Immunity After Xenogeneic DNA Immunization Against a Tumor Differentiation Antigen. J. Immunol. 170: 5188-5194 [Abstract] [Full Text]
Schmollinger, J. C., Vonderheide, R. H., Hoar, K. M., Maecker, B., Schultze, J. L., Hodi, F. S., Soiffer, R. J., Jung, K., Kuroda, M. J., Letvin, N. L., Greenfield, E. A., Mihm, M., Kutok, J. L., Dranoff, G. (2003). Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc. Natl. Acad. Sci. USA 100: 3398-3403 [Abstract] [Full Text]
Butterfield, L. H., Ribas, A., Dissette, V. B., Amarnani, S. N., Vu, H. T., Oseguera, D., Wang, H.-J., Elashoff, R. M., McBride, W. H., Mukherji, B., Cochran, A. J., Glaspy, J. A., Economou, J. S. (2003). Determinant Spreading Associated with Clinical Response in Dendritic Cell-based Immunotherapy for Malignant Melanoma. Clin. Cancer Res. 9: 998-1008 [Abstract] [Full Text]
Schaft, N., Willemsen, R. A., de Vries, J., Lankiewicz, B., Essers, B. W. L., Gratama, J.-W., Figdor, C. G., Bolhuis, R. L. H., Debets, R., Adema, G. J. (2003). Peptide Fine Specificity of Anti-Glycoprotein 100 CTL Is Preserved Following Transfer of Engineered TCR{alpha}{beta} Genes Into Primary Human T Lymphocytes. J. Immunol. 170: 2186-2194 [Abstract] [Full Text]
Horiguchi, Y., Nukaya, I., Okazawa, K., Kawashima, I., Fikes, J., Sette, A., Tachibana, M., Takesako, K., Murai, M. (2002). Screening of HLA-A24-restricted Epitope Peptides from Prostate-specific Membrane Antigen That Induce Specific Antitumor Cytotoxic T Lymphocytes. Clin. Cancer Res. 8: 3885-3892 [Abstract] [Full Text]
Lev, A., Novak, H., Segal, D., Reiter, Y. (2002). Recruitment of CTL Activity by Tumor-Specific Antibody-Mediated Targeting of Single-Chain Class I MHC-Peptide Complexes. J. Immunol. 169: 2988-2996 [Abstract] [Full Text]
Denkberg, G., Cohen, C. J., Lev, A., Chames, P., Hoogenboom, H. R., Reiter, Y. (2002). Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. Proc. Natl. Acad. Sci. USA 99: 9421-9426 [Abstract] [Full Text]
Hodi, F. S., Schmollinger, J. C., Soiffer, R. J., Salgia, R., Lynch, T., Ritz, J., Alyea, E. P., Yang, J., Neuberg, D., Mihm, M., Dranoff, G. (2002). ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc. Natl. Acad. Sci. USA 99: 6919-6924 [Abstract] [Full Text]
Schaed, S. G., Klimek, V. M., Panageas, K. S., Musselli, C. M., Butterworth, L., Hwu, W.-J., Livingston, P. O., Williams, L., Lewis, J. J., Houghton, A. N., Chapman, P. B. (2002). T-Cell Responses against Tyrosinase 368-376(370D) Peptide in HLA*A0201+ Melanoma Patients: Randomized Trial Comparing Incomplete Freund's Adjuvant, Granulocyte Macrophage Colony-stimulating Factor, and QS-21 as Immunological Adjuvants. Clin. Cancer Res. 8: 967-972 [Abstract] [Full Text]
Smith, S. G., Patel, P. M., Porte, J., Selby, P. J., Jackson, A. M. (2001). Human Dendritic Cells Genetically Engineered to Express a Melanoma Polyepitope DNA Vaccine Induce Multiple Cytotoxic T-Cell Responses. Clin. Cancer Res. 7: 4253-4261 [Abstract] [Full Text]
Mullins, D. W., Bullock, T. N. J., Colella, T. A., Robila, V. V., Engelhard, V. H. (2001). Immune Responses to the HLA-A*0201-Restricted Epitopes of Tyrosinase and Glycoprotein 100 Enable Control of Melanoma Outgrowth in HLA-A*0201-Transgenic Mice. J. Immunol. 167: 4853-4860 [Abstract] [Full Text]
Sutmuller, R. P.M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N.M., Wildenberg, M. E., Allison, J. P., Toes, R. E.M., Offringa, R., Melief, C. J.M. (2001). Synergism of Cytotoxic T Lymphocyte-associated Antigen 4 Blockade and Depletion of CD25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses. JEM 194: 823-832 [Abstract] [Full Text]
Lee, P., Wang, F., Kuniyoshi, J., Rubio, V., Stuges, T., Groshen, S., Gee, C., Lau, R., Jeffery, G., Margolin, K., Marty, V., Weber, J. (2001). Effects of Interleukin-12 on the Immune Response to a Multipeptide Vaccine for Resected Metastatic Melanoma. JCO 19: 3836-3847 [Abstract] [Full Text]
Jager, D, Jager, E, Knuth, A (2001). Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J. Clin. Pathol. 54: 669-674 [Abstract] [Full Text]
Niethammer, A. G., Xiang, R., Ruehlmann, J. M., Lode, H. N., Dolman, C. S., Gillies, S. D., Reisfeld, R. A. (2001). Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by an Autologous Oral DNA Vaccine against Murine Melanoma. Cancer Res. 61: 6178-6184 [Abstract] [Full Text]
Christ, O., Matzku, S., Burger, C., Zöller, M. (2001). Interleukin 2-Antibody and Tumor Necrosis Factor-Antibody Fusion Proteins Induce Different Antitumor Immune Responses in Vivo. Clin. Cancer Res. 7: 1385-1397 [Abstract] [Full Text]
Rakhmilevich, A. L., Imboden, M., Hao, Z., Macklin, M. D., Roberts, T., Wright, K. M., Albertini, M. R., Yang, N.-S., Sondel, P. M. (2001). Effective Particle-mediated Vaccination against Mouse Melanoma by Coadministration of Plasmid DNA Encoding Gp100 and Granulocyte-Macrophage Colony-Stimulating Factor. Clin. Cancer Res. 7: 952-961 [Abstract] [Full Text]
Christ, O., Seiter, S., Matzku, S., Burger, C., Zöller, M. (2001). Efficacy of Local versus Systemic Application of Antibody-Cytokine Fusion Proteins in Tumor Therapy. Clin. Cancer Res. 7: 985-998 [Abstract] [Full Text]
Le Borgne, R., Planque, N., Martin, P., Dewitte, F., Saule, S., Hoflack, B. (2001). The AP-3-dependent targeting of the melanosomal glycoprotein QNR-71 requires a di-leucine-based sorting signal. J. Cell Sci. 114: 2831-2841 [Abstract] [Full Text]
Kessler, J. H., Beekman, N. J., Bres-Vloemans, S. A., Verdijk, P., van Veelen, P. A., Kloosterman-Joosten, A. M., Vissers, D. C.J., ten Bosch, G. J.A., Kester, M. G.D., Sijts, A., Drijfhout, J. W., Ossendorp, F., Offringa, R., Melief, C. J.M. (2001). Efficient Identification of Novel HLA-A*0201-presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen PRAME by Proteasome-mediated Digestion Analysis. JEM 193: 73-88 [Abstract] [Full Text]
Shaif-Muthana, M., McIntyre, C., Sisley, K., Rennie, I., Murray, A. (2000). Dead or Alive: Immunogenicity of Human Melanoma Cells When Presented by Dendritic Cells. Cancer Res. 60: 6441-6447 [Abstract] [Full Text]
Cochlovius, B., Stassar, M., Christ, O., Raddrizzani, L., Hammer, J., Mytilineos, I., Zoller, M. (2000). In Vitro and In Vivo Induction of a Th Cell Response Toward Peptides of the Melanoma-Associated Glycoprotein 100 Protein Selected by the TEPITOPE Program. J. Immunol. 165: 4731-4741 [Abstract] [Full Text]
Jäger, E., Gnjatic, S., Nagata, Y., Stockert, E., Jäger, D., Karbach, J., Neumann, A., Rieckenberg, J., Chen, Y.-T., Ritter, G., Hoffman, E., Arand, M., Old, L. J., Knuth, A. (2000). Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl. Acad. Sci. USA 10.1073/pnas.220413497v1 [Abstract] [Full Text]
Gaiger, A., Reese, V., Disis, M. L., Cheever, M. A. (2000). Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 96: 1480-1489 [Abstract] [Full Text]
Colella, T. A., Bullock, T. N.J., Russell, L. B., Mullins, D. W., Overwijk, W. W., Luckey, C. J., Pierce, R. A., Restifo, N. P., Engelhard, V. H. (2000). Self-Tolerance to the Murine Homologue of a Tyrosinase-derived Melanoma Antigen: Implications for Tumor Immunotherapy. JEM 191: 1221-1232 [Abstract] [Full Text]
Vissers, J. L. M., De Vries, I. J. M., Schreurs, M. W. J., Engelen, L. P. H., Oosterwijk, E., Figdor, C. G., Adema, G. J. (1999). The Renal Cell Carcinoma-associated Antigen G250 Encodes a Human Leukocyte Antigen (HLA)-A2.1-restricted Epitope Recognized by Cytotoxic T Lymphocytes. Cancer Res. 59: 5554-5559 [Abstract] [Full Text]
Wang, F., Bade, E., Kuniyoshi, C., Spears, L., Jeffery, G., Marty, V., Groshen, S., Weber, J. (1999). Phase I Trial of a MART-1 Peptide Vaccine with Incomplete Freund's Adjuvant for Resected High-Risk Melanoma. Clin. Cancer Res. 5: 2756-2765 [Abstract] [Full Text]
Yamazaki, K., Spruill, G., Rhoderick, J., Spielman, J., Savaraj, N., Podack, E. R. (1999). Small Cell Lung Carcinomas Express Shared and Private Tumor Antigens Presented by HLA-A1 or HLA-A2. Cancer Res. 59: 4642-4650 [Abstract] [Full Text]
Toura, I., Kawano, T., Akutsu, Y., Nakayama, T., Ochiai, T., Taniguchi, M. (1999). Cutting Edge: Inhibition of Experimental Tumor Metastasis by Dendritic Cells Pulsed with {alpha}-Galactosylceramide. J. Immunol. 163: 2387-2391 [Abstract] [Full Text]
Perrin, G., Schnuriger, V., Quiquerez, A.-L., Saas, P., Pannetier, C., de Tribolet, N., Tiercy, J.-M., Aubry, J.-P., Dietrich, P.-Y., Walker, P. R. (1999). Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset. Int Immunol 11: 1337-1350 [Abstract] [Full Text]
Borges, L., Miller, R. E., Jones, J., Ariail, K., Whitmore, J., Fanslow, W., Lynch, D. H. (1999). Synergistic Action of fms-Like Tyrosine Kinase 3 Ligand and CD40 Ligand in the Induction of Dendritic Cells and Generation of Antitumor Immunity In Vivo. J. Immunol. 163: 1289-1297 [Abstract] [Full Text]
Kaplan, J. M., Yu, Q., Piraino, S. T., Pennington, S. E., Shankara, S., Woodworth, L. A., Roberts, B. L. (1999). Induction of Antitumor Immunity with Dendritic Cells Transduced with Adenovirus Vector-Encoding Endogenous Tumor-Associated Antigens. J. Immunol. 163: 699-707 [Abstract] [Full Text]
Butterfield, L. H., Koh, A., Meng, W., Vollmer, C. M., Ribas, A., Dissette, V., Lee, E., Glaspy, J. A., McBride, W. H., Economou, J. S. (1999). Generation of Human T-cell Responses to an HLA-A2.1-restricted Peptide Epitope Derived from {{alpha}}-Fetoprotein. Cancer Res. 59: 3134-3142 [Abstract] [Full Text]
Irvine, K. R., Parkhurst, M. R., Shulman, E. P., Tupesis, J. P., Custer, M., Touloukian, C. E., Robbins, P. F., Yafal, A. G., Greenhalgh, P., Sutmuller, R. P. M., Offringa, R., Rosenberg, S. A., Restifo, N. P. (1999). Recombinant Virus Vaccination against "Self" Antigens UsingAnchor-fixed Immunogens. Cancer Res. 59: 2536-2540 [Abstract] [Full Text]
Pardoll, D. M. (1999). Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA 96: 5340-5342 [Full Text]
Baar, J. (1999). Clinical Applications of Dendritic Cell Cancer Vaccines. The Oncologist 4: 140-144 [Full Text]
Greten, T. F., Jaffee, E. M. (1999). Cancer Vaccines. JCO 17: 1047-1047 [Abstract] [Full Text]
Palmieri, G., Strazzullo, M., Ascierto, P. A., Satriano, S. M.R., Daponte, A., Castello, G. (1999). Polymerase Chain Reaction-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression. JCO 17: 304-304 [Abstract] [Full Text]
Reynolds, S. R., Celis, E., Sette, A., Oratz, R., Shapiro, R. L., Johnston, D., Fotino, M., Bystryn, J.-C. (1998). HLA-Independent Heterogeneity of CD8+ T Cell Responses to MAGE-3, Melan-A/MART-1, gp100, Tyrosinase, MC1R, and TRP-2 in Vaccine-Treated Melanoma Patients. J. Immunol. 161: 6970-6976 [Abstract] [Full Text]
Kawakami, Y., Robbins, P. F., Wang, X., Tupesis, J. P., Parkhurst, M. R., Kang, X., Sakaguchi, K., Appella, E., Rosenberg, S. A. (1998). Identification of New Melanoma Epitopes on Melanosomal Proteins Recognized by Tumor Infiltrating T Lymphocytes Restricted by HLA-A1, -A2, and -A3 Alleles. J. Immunol. 161: 6985-6992 [Abstract] [Full Text]
Gueguen, M., Patard, J.-J., Gaugler, B., Brasseur, F., Renauld, J.-C., Van Cangh, P. J., Boon, T., Van den Eynde, B. J. (1998). An Antigen Recognized by Autologous CTLs on a Human Bladder Carcinoma. J. Immunol. 160: 6188-6194 [Abstract] [Full Text]
Bakker, A. B. H., Phillips, J. H., Figdor, C. G., Lanier, L. L. (1998). Killer Cell Inhibitory Receptors for MHC Class I Molecules Regulate Lysis of Melanoma Cells Mediated by NK cells, {gamma}{delta} T Cells, and Antigen-Specific CTL. J. Immunol. 160: 5239-5245 [Abstract] [Full Text]
Tureci, O., Sahin, U., Zwick, C., Koslowski, M., Seitz, G., Pfreundschuh, M. (1998). Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc. Natl. Acad. Sci. USA 95: 5211-5216 [Abstract] [Full Text]
de Zoeten, E. F., Carr-Brendel, V., Cohen, E. P. (1998). Resistance to Melanoma in Mice Immunized with Semiallogeneic Fibroblasts Transfected with DNA from Mouse Melanoma Cells. J. Immunol. 160: 2915-2922 [Abstract] [Full Text]
Kittlesen, D. J., Thompson, L. W., Gulden, P. H., Skipper, J. C. A., Colella, T. A., Shabanowitz, J. A., Hunt, D. F., Engelhard, V. H., Slingluff, C. L. Jr. (1998). Human Melanoma Patients Recognize an HLA-A1-Restricted CTL Epitope from Tyrosinase Containing Two Cysteine Residues: Implications for Tumor Vaccine Development. J. Immunol. 160: 2099-2106 [Abstract] [Full Text]
Valmori, D., Fonteneau, J.-F., Lizana, C. M., Gervois, N., Lienard, D., Rimoldi, D., Jongeneel, V., Jotereau, F., Cerottini, J.-C., Romero, P. (1998). Enhanced Generation of Specific Tumor-Reactive CTL In Vitro by Selected Melan-A/MART-1 Immunodominant Peptide Analogues. J. Immunol. 160: 1750-1758 [Abstract] [Full Text]
Jager, E., Chen, Y.-T., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jager, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., Old, L. J., Knuth, A. (1998). Simultaneous Humoral and Cellular Immune Response against Cancer-Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2-binding Peptide Epitopes. JEM 187: 265-270 [Abstract] [Full Text]
Morgan, D. J., Kreuwel, H. T. C., Fleck, S., Levitsky, H. I., Pardoll, D. M., Sherman, L. A. (1998). Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity. J. Immunol. 160: 643-651 [Abstract] [Full Text]
Osanto, S. (1997). Vaccine Trials for the Clinician: Prospects for Tumor Antigens. The Oncologist 2: 284-299 [Abstract] [Full Text]
Vierboom, M. P.M., Nijman, H. W., Offringa, R., Voort, E. I.H. v. d., Hall, T. v., Broek, L. v. d., Fleuren, G. J., Kenemans, P., Kast, W. M., Melief, C. J.M. (1997). Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes. JEM 186: 695-704 [Abstract] [Full Text]
Le Fur, N., Silvers, W. K., Kelsall, S. R., Mintz, B. (1997). Up-regulation of specific tyrosinase mRNAs in mouse melanomas with the c2j gene substituted for the wild-type tyrosinase allele: Utilization in design of syngeneic immunotherapy�models. Proc. Natl. Acad. Sci. USA 94: 7561-7565 [Abstract] [Full Text]
Wei, C., Willis, R. A., Tilton, B. R., Looney, R. J., Lord, E. M., Barth, R. K., Frelinger, J. G. (1997). Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: Implications for tolerance and�immunotherapy. Proc. Natl. Acad. Sci. USA 94: 6369-6374 [Abstract] [Full Text]
Le Fur, N., Kelsall, S. R., Silvers, W. K., Mintz, B. (1997). Selective increase in specific alternative splice variants of tyrosinase in murine melanomas: A projected basis for�immunotherapy. Proc. Natl. Acad. Sci. USA 94: 5332-5337 [Abstract] [Full Text]
Schmidt, W., Buschle, M., Zauner, W., Kirlappos, H., Mechtler, K., Trska, B., Birnstiel, M. L. (1997). Cell-free tumor antigen peptide-based�cancer�vaccines. Proc. Natl. Acad. Sci. USA 94: 3262-3267 [Abstract] [Full Text]
Hishii, M., Andrews, D., Boyle, L.�A., Wong, J.�T., Pandolfi, F., van�den�Elsen, P.�J., Kurnick, J.�T. (1997). In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic�sites. Proc. Natl. Acad. Sci. USA 94: 1378-1383 [Abstract] [Full Text]
Ropke, M., Hald, J., Guldberg, P., Zeuthen, J., Norgaard, L., Fugger, L., Svejgaard, A., Burg, S.�V.�D., Nijman, H.�W., Melief, C.�J.�M., Claesson, M.�H. (1996). Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived�peptide. Proc. Natl. Acad. Sci. USA 93: 14704-14707 [Abstract] [Full Text]
Sadovnikova, E., Stauss, H. J. (1996). Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: Reagents for tumor�immunotherapy. Proc. Natl. Acad. Sci. USA 93: 13114-13118 [Abstract] [Full Text]
Xiang, R., Lode, H. N., Chao, T.-H., Ruehlmann, J. M., Dolman, C. S., Rodriguez, F., Whitton, J. L., Overwijk, W. W., Restifo, N. P., Reisfeld, R. A. (2000). An autologous oral DNA vaccine protects against murine melanoma. Proc. Natl. Acad. Sci. USA 97: 5492-5497 [Abstract] [Full Text]
Jager, E., Gnjatic, S., Nagata, Y., Stockert, E., Jager, D., Karbach, J., Neumann, A., Rieckenberg, J., Chen, Y.-T., Ritter, G., Hoffman, E., Arand, M., Old, L. J., Knuth, A. (2000). Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl. Acad. Sci. USA 97: 12198-12203 [Abstract] [Full Text]